To our knowledge, MCP-1 is one of the NF-κB target genes, and the suppression of IKKβ/NF-κB-dependent inflammation is beneficial to improving IR and type 2 diabetes [20,36,37]. This evidence concerns the gene CCL2 and type 2 diabetes mellitus.